Sorafenib suppresses the rapid progress of hepatocellular carcinoma after insufficient radiofrequency ablation therapy: An experiment in vivo
- 1 March 2013
- journal article
- other
- Published by SAGE Publications in Acta Radiologica
- Vol. 54 (2), 199-204
- https://doi.org/10.1258/ar.2012.120249
Abstract
Background: Radiofrequency ablation (RFA) is a widely applied treatment for hepatocellular carcinoma (HCC), but insufficient RFA can promote rapid progression of the residual tumor through the hypoxia inducible factor-1α (HIF-1α)/vascular endothelial growth factor A (VEGFA) pathway. Although sorafenib has been successfully applied to advanced HCC, the use of sorafenib in residual tumor cells after RFA has rarely been tested. Purpose: To evaluate the potential role of sorafenib as an adjunct to RFA to reduce the recurrence rate after insufficient RFA. Material and Methods: Xenograft tumors of SMMC 7721 were created by subcutaneously inoculating nude mice with hepatoma cells (5× 106 cells per mouse). Fourteen days after inoculation, all mice were divided into three groups (control group [sham puncture], RFA group, and RFA combined with sorafenib treatment group) with six mice in each group. Each group was given a different treatment procedure. After treatment, the volume of the tumors was calculated from the resected specimens. The mRNA and protein expression of HIF-1a and VEGFA was quantified by real-time PCR and immunohistochemistry analysis. The micro-vessel density (MVD) was determined by CD34 immunohistochemistry. Results: Real-time PCR and immunohistochemistry analysis showed that, compared to the RFA group, HIF-1α and VEGFA expression were significantly decreased in the group that received RFA combined with sorafenib treatment ( P < 0.05). By comparing the control group with the RFA group, we found that insufficient RFA promoted HIF-1α and VEGFA expression ( P < 0.05). Similar results were obtained for MVD expression. Additionally, the combination of RFA with sorafenib therapy resulted in a synergistic reduction in tumor growth compared to insufficient RFA and sham puncture ( P < 0.05). Conclusion: Sorafenib was able to inhibit the expression of HIF-1α and VEGFA, and sorafenib was able to increase time to recurrence when used as an adjunct to RFA.Keywords
This publication has 25 references indexed in Scilit:
- EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinomaJournal of Hepatology, 2012
- The Current Role of Radiofrequency Ablation in the Management of Hepatocellular CarcinomaAnnals of Surgery, 2009
- Effect of Rapamycin Alone and in Combination with Sorafenib in an Orthotopic Model of Human Hepatocellular CarcinomaClinical Cancer Research, 2008
- Sorafenib in Advanced Hepatocellular CarcinomaThe New England Journal of Medicine, 2008
- Local Recurrence After Hepatic Radiofrequency CoagulationAnnals of Surgery, 2005
- Ischemia/reperfusion accelerates the outgrowth of hepatic micrometastases in a highly standardized murine modelJournal of Hepatology, 2005
- Targeting HIF-1 for cancer therapyNature Reviews Cancer, 2003
- VEGF and Tumour Angiogenesis. Impact of Surgery, Wound Healing, Inflammation and Blood TransfusionScandinavian Journal of Gastroenterology, 2002
- How should patients with hepatocellular carcinoma be staged?Cancer, 2000
- Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trialsJournal of Hepatology, 1999